PF-08634404 is a fully human immunoglobulin G4 bispecific antibody that simultaneously targets PD-1 and VEGF. Phase II studies have shown promising efficacy and manageable safety with PF-08634404 as monotherapy and with chemotherapy in 1L non-small cell lung cancer (NSCLC). This study will evaluate PF-08634404 in combination with different anticancer agents in advanced solid tumors including NSCLC.
Building similarity graph...
Analyzing shared references across papers
Loading...
E. Felip
Federico Cappuzzo
R. Martins
ESMO Open
Peking University
Virginia Commonwealth University
Pfizer (United States)
Building similarity graph...
Analyzing shared references across papers
Loading...
Felip et al. (Tue,) studied this question.
www.synapsesocial.com/papers/69bb92f2496e729e62980b8e — DOI: https://doi.org/10.1016/j.esmoop.2026.106457
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: